In melanoma, they can be used to
determine tumor stage, diagnosis, therapy selection and when to monitor for disease recurrence.
Not exact matches
To
determine local immune control, where the invasive tissue interfaces with normal cells, post-birth placentas and
stage - four melanoma
tumors were examined.
«By understanding what causes malignant transformation we can
determine what can be done for patients with benign
tumors to suppress them before they reach the malignant
stage,» Alman said.
Researchers wanted to
determine if ipilimumab could improve the survival of advanced -
stage melanoma patients if it was given after the surgical removal of both their primary melanoma
tumors and their regional lymph nodes.
Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(
Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1 • Known PD - L1
tumor status as
determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.
Our cancer experts
determine an individualized treatment plan based on the
stage of the cancer, the size and location of the
tumor, if the
tumor has spread to other organs or lymph nodes, and other factors such as overall health.
To develop new drugs and
determine what treatments are most appropriate for different
tumor stages, scientists need to work out what changes occur at a molecular and genetic level as a
tumor progresses.
Oncologists commonly use this imaging technique to help locate
tumors, establish the
stage of those cancers» progression, and
determine whether they have stopped growing in response to therapy or are relapsing or metastasizing.
If Ewing's sarcoma is the diagnosis, your doctor will
stage the
tumor, which
determines if and how far the cancer has spread.
identify disease in its earliest
stages and
determine the exact location of a
tumor, often before symptoms occur or abnormalities can be detected with other diagnostic tests
If Wilms
tumor is the diagnosis, your doctor will
stage the
tumor, which
determines if and how far the cancer has spread.
If a germ cell
tumor is the diagnosis, your doctor will
stage the
tumor, which
determines if and how far the cancer has spread.
Any
tumor that spreads anywhere is automatically
stage 4, but we have not
determined the
stage yet.»
The veterinarian will
determine the
tumors «
stage» based on size.
Once a diagnosis of TCC is made, it is important to
determine the extent of the
tumor, i.e. to perform «
tumor staging».
The pathologist will
determine the type of
tumor and will also
stage it.
The work - up and
staging are important for two reasons: it is necessary to
determine the
tumor type and extent of the cancer, but also provides the clinician with information regarding the dog's general health and may identify concurrent medical or musculoskeletal problems, all of which may influence the treatment recommendations.
These things are
determined by the grade and
stage of mast cell
tumor your pet has, as well as other health issues that may be present.
The purpose of our study was to
determine if specific host factors, such as age at diagnosis, obesity, and hormone status, influence the prognosis of canine mammary gland carcinomas and to confirm if previously reported risk factors (ie, histologic subtype,
tumor size, and World Health Organization [WHO]
stage) were important in a large series of affected dogs.